Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06124326 · ClinicalTrials.gov registry record · NA
A Single Group Study to Evaluate the Effects of a Supplement on Premenstrual Syndrome
A NA study, sponsored by Rael.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT06124326: Completed NA study, sponsored by Rael.
NCT06124326 is a NA study that has completed, run by Rael. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06124326, a NA study, has completed, sponsored by Rael.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a virtual single-group study that will last three menstrual cycles (approximately 12 weeks). During the first menstrual cycle, participants will take the supplement as needed (pro re nata) when they feel symptoms of PMS, such as cramping or bloating. For the second and third menstrual cycles, Participants will take 2 capsules per day with water for 1 week, starting 4 days before their menstrual cycle and finishing on Day 3 of their cycle. Questionnaires will be completed at the following time points: * Baseline * Day 7 of their first cycle during the trial (After using the product PRN during their period) * 4 days before their second period during the trial (After using the product PRN for the previous month) * Day 3 of their second period during the trial (After using the product for 7 days straight) * Day 3 of their third period of the trial (After using the product for 7 days straight)
Primary Outcome
Participants will complete study-specific questionnaires. Questionnaires will include 5-point Likert scale, with 5 representing the most favorable/best outcome (e.g., "Not at all") and 1 representing the least favorable/worst outcome (e.g., "Severe").
Interventions
- DIETARY_SUPPLEMENT Premenstrual Syndrome Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-08-31 |
| Est. Completion | 2024-01-20 |
| Phase | NA |
What the finished NCT06124326 record still lists
NCT06124326 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Premenstrual Syndrome Supplement is the first listed.
NCT06124326 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06124326 about?
NCT06124326 is a clinical study titled "A Single Group Study to Evaluate the Effects of a Supplement on Premenstrual Syndrome". This is a virtual single-group study that will last three menstrual cycles (approximately 12 weeks). During the first menstrual cycle, participants will take the supplement as needed (pro re nata) when they feel symptoms of PMS, such as cramping or bloating. For the second and third menstrual cycles...
What is the current status of trial NCT06124326?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2023-08-31. Estimated completion is 2024-01-20.
What interventions are being tested in trial NCT06124326?
The interventions under investigation include: Premenstrual Syndrome Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06124326?
This trial is sponsored by Rael, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06124326's enrollment target sits among peer trials
40 1447th of 2000 higher than 465 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI